强化化疗联合酪氨酸激酶抑制剂治疗新发BCR::ABL1阳性急性髓系白血病
该回顾性研究分析了212例新发BCR::ABL1阳性急性髓系白血病成人患者,比较强化化疗联合或不联合酪氨酸激酶抑制剂的疗效。联合TKI显著提高完全缓解/完全缓解伴血液学不完全恢复率(89% vs 68%,P<0.0001)及总生存率,多因素分析显示联合TKI是独立预后良好因素,作者建议将其作为标准治疗并重新考虑ELN危险分层。
要点
- 强化化疗联合TKI显著提高CR/CRi率(89% vs 68%,P<0.0001)。
- 联合TKI组中位OS未达到,3年OS率70.9% vs 42.1%(P<0.0001)。
- 联合TKI是CR/CRi和OS的独立预后良好因素(OR 4.74,HR 0.40)。
核心结论
- 在新发BCR::ABL1阳性AML中,强化化疗联合TKI显著改善完全缓解率和总生存,应成为标准治疗。
- 作者建议未来ELN分类重新考虑该亚型的不良风险归属。
研究设计与样本
- 回顾性分析212例成人AML患者,骨髓原始细胞≥20%,BCR::ABL1阳性或t(9;22)(q34.1;q11.2),无既往CML病史及BCR-ABL1 TKI暴露史。
- 89例接受单纯强化化疗,123例接受强化化疗联合TKI,治疗时间1999年至2024年。
主要发现
- CR/CRi率:单纯强化化疗组52/77例(68%),联合TKI组110/123例(89%),P<0.0001。
- 中位随访66.7个月,中位OS:单纯强化化疗组20.5个月,联合TKI组未达到。
- 3年和5年OS率:单纯强化化疗组42.1%和38.5%,联合TKI组70.9%和62.9%,P<0.0001。
- 多因素分析:联合TKI与CR/CRi改善独立相关(OR 4.74,95%CI 2.17-10.35,P<0.001),与OS改善独立相关(HR 0.40,95%CI 0.27-0.62,P<0.001)。
- 联合TKI(HR 0.42,95%CI 0.23-0.75,P=0.004)和CR1期异基因造血干细胞移植(HR 0.31,95%CI 0.17-0.55,P<0.0001)是无复发生存的独立预后因素。
临床怎么用
- 对于新发BCR::ABL1阳性AML,强化化疗方案中应联合TKI以提高缓解率和生存。
- CR1期应考虑异基因造血干细胞移植,因其与无复发生存改善独立相关。
局限性
- 回顾性研究设计,可能存在选择偏倚。
- 单纯强化化疗组CR/CRi评估仅77例可评估,样本量较小。
- 研究跨越1999年至2024年,治疗方案和支持治疗可能随时间变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To describe the impact of adding a tyrosine kinase inhibitor (TKI) to intensive chemotherapy (IC) on the outcome of de novo BCR::ABL1+ acute myeloid leukemia (AML), we retrospectively analyzed the data of 212 adult AML with ≥20% bone marrow blasts, BCR::ABL1+ or t(9;22)(q34.1;q11.2), no history of previous chronic myeloid leukemia and no prior exposure to BCR-ABL1 TKI. Eighty-nine patients were treated with IC alone and 123 with IC+TKI between 1999 and 2024. Complete remission (CR) or CR with incomplete hematologic recovery (CRi) was achieved in 52/77 patients (68%) with IC and 110/123 patients (89%) with IC+TKI (P<0.0001). With a median follow-up of 66.7 months, the median overall survival (OS) was 20.5 months with IC and not reached with IC+TKI. The 3-year and 5-year OS rates were 42.1% and 38.5% with IC and 70.9% and 62.9% with IC+TKI (P<0.0001) respectively. In multivariate analyses, the addition of TKI to IC was significantly and independently associated with an improved CR/CRi rate (odds ratio: 4.74 [95% confidence interval: 2.17-10.35]; P<0.001) and OS (hazard ratio: 0.40 [0.27-0.62]; P<0.001). Also, adding TKI to IC and alloHSCT in CR1 were independent prognostic factors for relapse-free survival (HR: 0.42; 95% CI: 0.23-0.75; P=0.004 and HR: 0.31; 95% CI: 0.17-0.55; P<0.0001). The outcome of de novo BCR::ABL1+ AML is strongly improved by the addition of a TKI to IC and should become the standard of care. The classification as adverse-risk should be reconsidered in the future ELN classification.
引用
- Bertoli S, Landberg N, Bérard E, et al. Intensive Chemotherapy and Tyrosine Kinase Inhibitor in Patients with De Novo BCR::ABL1+ Acute Myeloid Leukemia. Blood. 2026. PMID: 42758645. doi:10.1182/blood.2026033895
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。